

Appendix B: Disease costing methodology

The Disease Costs and Impact Study (DCIS), a joint project of the AIHW and the National Centre for Health Program Evaluation, has developed a methodology for specific diseases and disease groups in Australia (Mathers et al. 1998b). The basic approach for direct costs of health services has been to take known aggregate expenditures on health care and apportion those to disease categories using Australian data (hospital morbidity data, casemix data, the national survey of morbidity and treatment in general practice, and the 1989–90 National Health Survey). The DCIS methodology is documented in detail in Mathers et al. (1998b).

Total recurrent health expenditure in 1993–94 as reported by the AIHW (1996) is disaggregated by the following dimensions:

- Disease (defined by ICD-9 code groups — see Appendix A)
- Sector (hospital inpatient, non-inpatient, medical, pharmaceutical etc.)
- Program (treatment, prevention)
- Sex (male, female)
- Age (0–4, 5–14, 15–24, 65–74, 75+).

The proportion of direct health expenditure included in the disease costings in this report represents just over 90% of direct health care expenditure (see Table B.1 for a list of the health sectors included). Recurrent expenditure on health care which has not yet been attributed includes ambulance services, community health services, health promotion and illness prevention (apart from breast, cervix, lung and skin cancer public health programs), ambulance services, and medical aids and appliances.

The attribution of the direct costs of health services to disease is discussed in more detail below and summarised in Table B.1.

Hospital inpatient services

This sector includes inpatient (admitted patient) costs for recognised public hospitals (including public psychiatric hospitals), repatriation (veterans') hospitals and private hospitals. The proportions of total public acute hospital expenditure which relate to inpatients are given by the inpatient fractions estimated for each State and Territory by the National Health Ministers, Benchmarking Working Group (1996).

Disease costs for inpatient services are estimated by apportioning the total inpatient expenditure for each State or Territory to individual episodes of hospitalisation with an adjustment for resource intensity of treatment for the specific episode (using DRGs). Medical costs for private, compensable and other non-public patients in public, repatriation and private hospitals are estimated using DRG-derived medical

cost weights and age–sex specific information from the Health Insurance Commission on in-hospital private medical charges for various categories of service. Public psychiatric hospital data for NSW and Victoria are used to allocate public psychiatric hospitals inpatient costs. These costs all fall in the mental health chapter of ICD-9.

Outpatient and casualty services

The 1989–90 ABS National Health Survey is used to allocate total expenditure on non-inpatient services for 1993–94. Total visits to outpatient clinics (including casualty or accident and emergency departments) for each age–sex–disease group are estimated from the National Health Survey data on numbers of outpatient visits in the two weeks prior to interview. Expenditure is allocated assuming that all visits have the same cost.

Nursing homes

The distribution of main disabling health condition of nursing home residents in the ABS 1993 Australian Survey of Disability, Ageing and Carers is used to allocate total nursing home expenditure for 1993–94 to age–sex–disease categories at ICD-9 chapter level. Costs are distributed in proportion to the distribution of main disabling condition at the time of the survey. This assumes that the average per day cost of nursing home care is the same for all patients irrespective of diagnosis. Estimated expenditure at chapter level is apportioned to specific disease groups at the sub-chapter level according to the distribution of diagnosis for patients in that age–sex group who transfer from acute hospitals (around 60% of nursing home admissions).

Medical services

This sector includes expenditure on all private medical services apart from those to hospital inpatients. It includes consultations with general practitioners and specialists as well as pathology tests and screening and diagnostic imaging services. The 1990–91 Survey of Morbidity and Treatment in General Practice in Australia (GP survey) is used to allocate age–sex specific out-of-hospital expenditure on medical services to disease diagnoses. This allocation is done separately for general practitioners (based on encounters surveyed in the GP survey) and for 17 categories of specialists (based on the pattern of referrals to each category of specialist in the GP survey).

Age–sex specific out-of-hospital expenditure on medical services is derived from Medicare and Department of Veteran's Affairs (DVA) data. This expenditure covers all charges for which a Medicare or DVA claim has been made. It is adjusted to include expenditure for which claims have not been made using an inflation factor derived from the AIHW health expenditure data on total expenditure on medical services.

This methodology assumes that the pattern of GP services by diagnosis in 1993–94 is the same as that collected in 1990–91, that the pattern of diseases managed by each type of specialist in 1993–94 reflects the pattern of referrals to that specialist type from GPs in 1990–91 and that each referral to a specialist of a given type generates

services with equal cost. Estimates of numbers of services and costs for pathology screening tests for cervix and prostate cancer were adjusted to reflect total Medicare claims and charges for 1993–94 for Pap smears and PSA tests respectively. Utilisation and costs for Pap smears were adjusted upwards by a factor of 1.38 to take account of Pap smears read in public laboratories (Dankiw 1994).

All other screening and diagnostic tests apart from screening mammography (see *Public health programs* below) were costed based on the 1990–91 pattern of referrals by GPs using the overall average charge per pathology test in 1993–94.

Allied health services

The 1990–91 Survey of Morbidity and Treatment in General Practice in Australia and the 1989–90 ABS National Health Survey are used to allocate total Australian expenditure on allied health practitioners to age–sex–disease groups. Total visits to allied health practitioners in 1993–94 for each age–sex–disease group are estimated from the National Health Survey data on visits to 14 types of allied health practitioners in the two weeks prior to interview. Annual visits to other types of allied health practitioner are estimated from referrals by GPs in the GP survey. Expenditure is allocated assuming that all visits have the same cost. The methodology covers all allied health professionals except pharmacists (see below). Costs for dental services are allocated to the 'Digestive system' chapter of ICD–9 and account for the very large allied health expenditure for that chapter (see Table 1).

Pharmaceuticals

Total pharmaceutical expenditure is decomposed into two components: expenditures on prescription drugs and non–prescription (over-the-counter) pharmaceuticals. The 1990–91 Survey of Morbidity and Treatment in General Practice in Australia together with 1993–94 estimates of total costs and numbers of prescriptions for 40 categories of drug are used to allocate total Australian expenditure on prescription pharmaceuticals to age–sex–disease groups. Expenditure on over-the-counter pharmaceuticals is attributed to disease–age–sex groups using information from the 1989–90 ABS National Health Survey. The methodology addresses all pharmaceutical costs apart from the cost of pharmaceuticals dispensed in hospitals, which are included in estimates of hospital costs.

For each of 40 therapeutic drug groups (Pharmaceutical Benefits Pricing Authority 1994), the relative distribution of prescriptions by disease, age and sex for all community prescriptions in 1993–94 is assumed to be the same as that for prescriptions by general practitioners in 1990–91. For diseases where a significant proportion of prescriptions are made by medical specialists, this assumption may have limited validity. Detailed estimates of 1993–94 utilisation and expenditure for the 40 drug categories are used as a starting point for attribution to disease–age–sex groups. This takes into account differences in average drug costs across therapeutic categories, average numbers of repeats and relative changes in utilisation and costs across drug categories between 1989–90 and 1993–94.

There were an estimated 431,000 prescriptions in 1993–94 for anti-neoplastic and immunosuppressant drugs, at an average cost per prescription of \$120, an order of magnitude greater than the average cost per prescription of \$19 for all other drugs. As noted above, the methodology takes account of the high cost of these drugs.

Public health programs

Community and public health programs in general are not yet included in the estimates of disease costs due to the difficulties in obtaining comprehensive casemix data for these health sectors. However, estimates of the costs for the breast and cervical cancer national screening programs and for lung and skin cancer prevention programs have been included for this report.

Costs of mammographic screening for breast cancer under the National Program for the Early Detection of Breast Cancer are funded outside the Medicare scheme on an equal dollar-for-dollar basis by the Commonwealth and the States and Territories. The total cost of this program is estimated as double the expenditure by the Commonwealth Department of Health and Family Services in 1993–94 (Richardson et al. 1996) and the age distribution of screening obtained from evaluation data (Commonwealth Department of Human Services and Health 1994).

Costs for taking and reading Pap smears under the Organised Approach to Cervical Cancer Screening in Australia are covered by Medicare and are estimated using Medicare data as described above under *Medical services*. The additional costs of recruitment, coordination, registry and quality control reporting are funded on an equal dollar for dollar basis by the Commonwealth and the States and Territories. These additional costs are estimated as double the expenditure by the Commonwealth Department of Health and Family Services in 1993–94 (Richardson et al. 1996) and included under the *Public health* sector.

Public health program costs associated with the prevention of lung cancer have been estimated as a proportion of the total costs of anti-smoking programs in Australia in 1993–94. Michelle Scollo (personal communication, 1998) has estimated that total State and Territory and non-government expenditure on anti-smoking health education programs comprised \$14.9 million in 1993–94. To this estimate has been added an estimated \$2 million for tobacco legislation enforcement at State and Territory level, and \$1.1 million in Commonwealth expenditure. The latter figure comprises an estimated \$0.17 million in tobacco-specific programs under the National Drug Strategy and 50% of the National Drug Strategy funding of \$1.9 million for school and other general drug education programs (the total expenditure on the National Drug Strategy amounted to \$31.1 million in 1993–94).

Total 1993–94 expenditure on anti-smoking activity was thus estimated at \$18.0 million. Lung cancer accounts for around 25% of the total disease burden attributable to tobacco smoking (English et al. 1995), so 25% of \$18.0 million, or \$4.5 million, was identified as public health expenditure related to lung cancer. The other \$13.5 million is not included in the disease cost estimates for other diseases at this stage (the costs attributable to prevention of other smoking-related cancers are quite small). The 'lung cancer' expenditure of \$4.5 million is allocated to age–sex groups in proportion to the number of smokers in each age–sex group in 1993.

Public health program costs for the prevention of skin cancer in 1993–94 are based on estimates by Carter et al. (1997). These are attributed to melanoma and non-melanocytic skin cancer on a 50:50 basis.

Research

Estimated total Australian expenditure on health and medical research for major disease and population groups in 1991 (Nicholl et al. 1994) was used to attribute 1993–94 total research spending to chapters of ICD-9. This resulted in an estimated

\$74.4 million for cancer research in 1993–94. An analysis was carried out of the distribution of NHMRC grants for 1996 (NHMRC 1996) and of grants by the NSW Cancer Council and the Victorian Anti-Cancer Council. These data were used to make preliminary estimates of the distribution of research funding across cancer sites. A more detailed analysis of NHMRC and ABS data on research expenditure is being undertaken by AIHW for future disease cost estimates.

Other institutional, non-institutional and administration

Other institutional health expenditure (the Red Cross Blood Transfusion Service), other non-institutional health expenditure (Family Planning Services) and administration expenditure (Commonwealth, State and Territory health authority administration expenses and management expenses of Medicare and registered private health insurance funds) are allocated to disease–sex–age groups in proportion to total health expenditure for other health sectors.

Table B.1: Summary of methods: health system costs of cancer in Australia, 1993–94

Health sector	Basis of cost attribution to disease–age–sex groups	Data sources
Hospitals		
Acute hospital inpatients repatriation hospital inpatients	Separations weighted by DRG cost weight and length of stay	AIHW National Hospital Morbidity Database 1993–94
Public psychiatric hospital inpatients	Bed days	AIHW National Hospital Morbidity Database 1993–94
Hospital non-inpatients	For all cancers combined: number of visits in last 2 weeks. Attribution to specific cancer sites on basis of distribution of inpatient separations by site.	National Health Survey 1989–90 AIHW National Hospital Morbidity Database 1993–94
Medical services		
In-hospital medical services for private, compensable and other patients	Separations weighted by DRG-based estimated medical service cost weights.	Medicare data on fees charged for eligible in-hospital medical services in 1993–94 AIHW National Hospital Morbidity Database 1993–94
Out-of-hospital medical services	GP encounters weighted by Medicare schedule fee. Specialist referrals by GPs, weighted by Medicare data on fees charged.	Medicare data on fees charged for eligible out-of-hospital medical services in 1993–94 Australian Survey of Morbidity and Treatment in General Practice 1990–91
Pharmaceuticals		
Prescription drugs	Prescriptions weighted by relative utilisation and average prescription cost for therapeutic drug group	Pharmaceutical Benefits Scheme utilisation and cost data for 1993–94 Australian Survey of Morbidity and Treatment in General Practice 1990–91
Over-the-counter medicines	Use of non-prescription medications in the last two weeks	National Health Survey 1989–90
Allied health services		
	Reported visits in the last 2 weeks together with referrals by GPs	National Health Survey 1989–90 Australian Survey of Morbidity and Treatment in General Practice 1990–91
Nursing homes		
	For all cancers combined: number of residents by main disabling condition. Attribution to specific cancer sites on basis of distribution of transfers from acute hospitals.	Survey of Disability, Ageing and Carers 1993 AIHW National Hospital Morbidity Database 1993–94.
Other^(a)		
Public health	Estimated costs for breast and cervical cancer national screening programs and for lung and skin cancer prevention programs. Costs of other public health programs not included as yet.	Harris and Scott (1995), Richardson et al. (1996), Carter et al. (1997) Medicare data on fees charged for Pap smears and PSA tests in 1993–94
Research	Estimated expenditure for major disease groups from Nicholl et al. Distributed to detailed age–sex–disease groups in proportion to NHMRC and other relevant grant distributions.	Nicholl et al. (1994) NHMRC (1996)
Other institutional, administration and other non-institutional	Allocated to disease–age–sex groups in proportion to total expenditure in other categories	n.a.